Treating persistent depressive symptoms in post-ACS patients: the project COPES phase-I randomized controlled trial
Related Experiment Video
Updated: Jul 11, 2026

Polar Histogram Visualization of Acute Stress Disorder Scale Scores for Comprehensive Clinical Assessment
Published on: December 6, 2024
Matthew M Burg1, Francois Lespérance, Nina Rieckmann
1Behavioral Cardiovascular Health & Hypertension Program, Columbia University School of Medicine, New York City, NY 10032, United States. mb2358@columbia.edu
Insights
Project COPES is a clinical trial evaluating depression treatment for patients after acute coronary syndrome (ACS). It focuses on patient satisfaction and acceptability, informing future research on depression
Area of Science:
- Cardiology and Psychiatry
- Psychosocial aspects of cardiovascular disease
Background:
- Depression and sub-syndromal symptoms are significant predictors of morbidity and mortality post-acute coronary syndrome (ACS).
- Previous depression treatment trials in post-ACS patients showed no improvement in event-free survival and only modest symptom reduction.
- Key issues identified include optimal timing, patient acceptability, and safety of depression interventions in this population.
Purpose of the Study:
- To describe Project COPES (Coronary Psychosocial Evaluation Studies), a multi-center Phase-I randomized clinical trial.
- To evaluate patient preference depression treatment and a pre-randomization observation period for depression status.
- To inform subsequent clinical trials by providing data on patient satisfaction, treatment acceptability, symptom reduction, medication adherence, and inflammation.
Main Methods:
- A multi-center, Phase-I randomized clinical trial involving 200 post-ACS patients.
- Utilizes a patient preference depression treatment model.
- Includes a 3-month pre-randomization observation period to confirm depression status.
Main Results:
- Primary outcome: Patient satisfaction with depression care.
- Secondary, exploratory outcomes: Acceptability of depression treatment, reduction in depressive symptoms.
- Exploratory aims: Effects of treatment on medication adherence and inflammation as potential mediators linking depression to post-ACS prognosis.
Conclusions:
- Project COPES addresses critical issues in depression treatment for post-ACS patients, including timing, acceptability, and safety.
- The study prioritizes patient satisfaction and acceptability of depression care.
- Findings will guide the design of future, larger clinical trials investigating depression's impact on cardiovascular outcomes.
Abstract:
Depression and sub-syndromal depressive symptoms are important predictors of morbidity and mortality after acute coronary syndrome (ACS). Prior trials of depression treatment in post-ACS patients have demonstrated no improvement for event-free survival, and only modest improvement in depression symptoms. These trials have raised a number of important issues regarding timing of depression intervention, acceptability of depression treatment to ACS patients, and safety for subsets of the treated population. This article describes Project COPES (Coronary Psychosocial Evaluation Studies), a multi-center Phase-I randomized clinical trial. Project COPES uses a patient preference depression treatment that has previously been found acceptable to medical patients, and a 3-month pre-randomization observation period to insure depression status. The study sample will include 200 post-ACS patients. The primary outcome is patient satisfaction with depression care. Secondary, exploratory aims include the acceptability of depression treatment, reduction in depressive symptoms, and the effects of treatment on two key pathways--medication adherence and inflammation--hypothesized to link depression to post-ACS prognosis. These analyses will provide important data to inform subsequent clinical trials with this population.
Related Concept Videos
Acute Coronary Syndrome IV: Interprofessional Care
Acute Coronary Syndrome V: Nursing Management
